Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

Inclusion Criteria:

Participants must have ulcerative colitis or Crohn's disease with low grade dysplasia or polyploid dysplasia or have a history of dysplasia and increased positive beta-catenin levels confirmed by a consensus of the study pathologists (2 of 2, or 2 of 3)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Absolute neutrophil count (ANC) > 1,500/uL
Platelets > 100,000/uL
Total bilirubin within normal institutional limits
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT] =< 1.5 times upper limit of normal
Creatinine within normal institutional limits
International normalized ratio (INR) < 1.5
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of baseline pregnancy test, throughout the duration of the study, and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study and followed until the birth of the child
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Subjects with life-threatening medical conditions that would preclude study treatment intervention and colonoscopy
Participants may not be receiving any other investigational agents
History of allergic reactions to rice or compounds of similar chemical or biologic composition to myo-inositol (i.e., urticaria, dermatologic reaction)
Use of medications known to elevate serum blood glucose; participants on steroids are still eligible, as they will be monitored weekly for fasting blood glucose
Participants with dysplasia-associated lesion or mass (DALM), high-grade dysplasia or invasive colonic carcinoma are excluded

Uncontrolled intercurrent illness including, but not limited to

Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Chronic renal failure
Chronic renal insufficiency
Psychiatric illness or social situations that would limit compliance with study requirements
Prior treatment with myo-inositol
History of systemic chemotherapy within 18 months of screening
Subjects taking valproic acid and/or lithium
Diabetes mellitus
History of total proctocolectomy
Concomitant primary sclerosing cholangitis (PSC)
Pregnant or lactating subjects are excluded